Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis

A Meta-Analysis

Yanjie Hou, MD, Ke Gu, MD, Chao Xu, MD, Huiyong Ding, MD, Changxin Liu, PhD, and Yilihamu Tuoheti, MD

Abstract: The purpose of this study was to perform a meta-analysis on the efficacy of ibandronate by evaluating the effect sizes of different dosing regimens.

Major electronic databases were searched from 1985 to February 2015. A random effects meta-analysis was performed in STATA. Data from 34 studies (13,639 patients) were included in this meta-analysis. Ibandronate treatment significantly improved lumbar spine bone mineral density (BMD) as shown by the percent change from baseline (4.80%, \( P < 0.0001 \), 95% confidence interval [CI] [4.14, 5.45]). The respective effect sizes for oral intake and intravenous (IV) infusion were 4.57% and 5.22% \( (P < 0.0001) \), CIs [3.71, 5.42] and [4.37, 6.07], respectively. All doses led to a significant increase in BMD except 2 oral dose regimens (1 mg/d: 4.65%, \( P = 0.285, 95\% \) CI [−3.87, 13.18] and 0.5 mg/d: 3.60%, \( P = 0.38, 95\% \) CI [−4.43, 11.64]). Ibandronate treatment (overall as well as dose wise) also significantly improved the total hip BMD—2.30% overall, 2.13% oral, and 2.63% IV (\( P < 0.0001 \), 95% CIs [1.96, 2.64]; [1.70, 2.55]; and [2.07, 3.20]), respectively. Ibandronate administration significantly decreased serum markers of bone resorption to −46.53% for C-terminal telopeptide of type I collagen, −24.03% for bone-specific alkaline phosphatase, and −50.17% for procollagen type 1 N-terminal propeptide (\( P < 0.0001 \), 95% CIs [−53.16, −39.91]; [−31.28, −16.77]; and [−64.13, −36.20]), respectively. Parathyroid hormone levels remained unaffected by ibandronate treatment (3.03%, \( P = 0.439, 95\% \) CI [−5.06, 11.66]).

There was no significant difference in the efficacy of ibandronate between oral or IV administration. Predominant dose regimens for IV administration were 1 to 3 mg/3 mo and 150 mg/mo oral and 2.5 mg/d, between oral or IV administration. Predominant dose regimens for IV treatment (3.03%, \( P = 0.38, 95\% \) CI [−4.43, 11.64]). Ibandronate treatment (overall as well as dose wise) also significantly improved the total hip BMD—2.30% overall, 2.13% oral, and 2.63% IV (\( P < 0.0001 \), 95% CIs [1.96, 2.64]; [1.70, 2.55]; and [2.07, 3.20]), respectively. Parathyroid hormone levels remained unaffected by ibandronate treatment (3.03%, \( P = 0.439, 95\% \) CI [−5.06, 11.66]).

INTRODUCTION

Osteoporosis is a state of bone fragility that increases susceptibility of the patients to fractures. It is an important global public health concern with both societal and economic implications. About 75 million people in the United States, Europe, and Japan suffer from osteoporosis.\(^1\) It is estimated that the incidence of hip fracture will increase by up to 240% in women and 310% in men by the year 2050.\(^2\)

Osteoporosis is strongly associated with age and causes significant morbidity and mortality in the elderly, affecting both men and women. Although osteoporotic fractures can occur anywhere in the skeletal system, vertebral, hip, and wrist fractures are most common. Vertebral fractures may cause height loss and respiratory dysfunction, which subsequently leads to reduced quality of life, social withdrawal, and morbidity.\(^3,4\) Hip fractures are associated with significantly increased mortality rates, with most mortality events occurring within 3 to 6 months after the event.\(^5\) The lifetime risk of fracture incidence is higher in women. Ten-year fracture risk at 50 years of age is 9.8% in women and 7.1% in men, which increases to 21.7% and \( 8\% \), respectively, by 80 years of age.\(^6\)

Therapeutic options for the management of osteoporotic fractures include the use of bisphosphonates, parathyroid hormone (PTH) analogs, selective estrogen receptor modulators, denosumab (antireceptor activator of nuclear factor-\( \kappa \) B ligand antibody), ibandronate, risedronate, and zoledronate are more efficacious.\(^5\) Alendronate, ibandronate, and zoledronate are more efficacious.\(^5\) Oral intake leads to \( 8\% \), respectively, by 80 years of age.\(^6\)

osteoproteostasis-mediated bone resorption.\(^5\) Although, non-nitrogenous bisphosphonates such as clodronate and etidronate are also used, nitrogenous bisphosphonates such as alendronate, ibandronate, risedronate, and zoledronate are more efficacious.\(^5\)

An inherent constraint in the use of bisphosphonates is their poor bioavailability. Oral intake leads to \( 1\% \) absorption in the gut. Moreover, fasting prior to administration is required and the patient must not lie down for 30 minutes following administration because these drugs cause esophageal irritation.\(^7\) This has led to poor patient compliance and compromised treatment efficacy. Alternatively, bisphosphonates can be infused via the intravenous (IV) route, which greatly enhances their bioavailability and reduces the frequency of administration compared to oral intake.

Despite the superior efficacy of IV infusions, oral intake of bisphosphonates remains common. Ibandronate is a preferable option within the bisphosphonate group as it offers relatively

**Abbreviations:** BSAP = bone-specific alkaline phosphatase, CI = confidence interval, CTX = C-terminal telopeptide of type 1 collagen, IV = intravenous, PINP = procollagen type I N-terminal propeptide, PMO = postmenopausal osteoporosis, PTH = parathyroid hormone, sPINP = serum procollagen type I N-terminal propeptide.
flexible dosing formulations and intake schedules. A number of trials have attempted to examine the efficacy of either oral intake or IV infusion of the bisphosphonates; others have compared both regimens. However, there is a paucity of trials with placebo-controlled designs. The objective of this study was to carry out a random effects meta-analysis, pooling data from trials focusing on the dose-effectiveness relationships of ibandronate therapy and the efficacy of oral versus IV administration.

**METHOD**

**Ethical Review**

Meta-analysis does not involve ethical review.

**Literature Search**

Several electronic databases including EBSCO, Embase, Google Scholar, Ovid SP, PubMed, Scopus, and Web of Science were used for the literature search. The major medical subject headings and keywords—bisphosphonates, nitrogen containing bisphosphonates, ibandronate, osteoporosis, fracture, bone mineral density (BMD), calcium, phosphate, lumbar spine, vertebral, hip, osteocalcin, sclerostin, C-terminal telopeptide of type I collagen (CTX), bone-specific alkaline phosphatase (BSAP), procollagen type I N-terminal propeptide (PINP), PTH, vitamin D, clinical trial, oral, IV, etc—were used in different logical combinations and phrases. The search encompassed original research articles published from 1985 to February 2015.

**Inclusion and Exclusion Criteria**

The inclusion criteria were trials recruiting osteoporosis patients or vulnerable populations to study the efficacy and safety of the ibandronate for at least 1 year period; where BMD of lumbar spine and/or total hip was measured; and providing baseline and final values or percent change from baseline. Exclusion criteria were trials utilizing ibandronate for purposes other than skeletal improvement; to assess patient adherence only; in combination with other therapeutic regimens such as PTH; to study the safety profile only; and with relevant but inadequate information for the meta-analysis.

**Data Extraction, Synthesis, and Statistical Analyses**

Important information including outcome measures and outcomes, primary and secondary endpoints, dosage and mode of administration, serum markers of osteoporosis development/improvement, BMD, and participants’ demographic characteristics were extracted onto datasheets. The meta-analysis was carried out by using Stata software (Version 12; StataCorp, College Station, TX). The random effects model was used, pooling the means and standard deviations of the variables of interest from all relevant studies. The effect sizes of subgroups were then subjected to a z test in order to evaluate the significance of difference. Statistical heterogeneity between the studies was tested by $I^2$ index. Sensitivity analyses were performed, wherever necessary. Egger and Begg tests were performed to examine the publication bias.

**FIGURE 1.** Flowchart of literature search, study screening, and selection process. *Results of 34 studies were published in 45 articles.*
RESULTS

Thirty-four studies fulfilled the eligibility criteria. Results of these trials were published in 45 articles and a flowchart summarizing study screening and the selection process is presented in Figure 1. Briefly, the following studies were included in the meta-analysis: 28 randomized controlled, 1 nonrandomized controlled, 4 prospective observational, and 1 retrospective study. Of the studies included, their important characteristics are presented in Table S1, http://links.lww.com/MD/A306. Publication bias tests indicated the chances of significant bias (Table S2, http://links.lww.com/MD/A306; Figures S1a and b, http://links.lww.com/MD/A306).

Overall, 11,090 patients received ibandronate, whereas 2549 patients were used as placebo controls. Among the ibandronate-treated patients, 7531 were administered oral ibandronate and 3559 received it as IV infusions. Among the important demographic data, age, height, weight, and body mass index as mean and standard deviation were 62.44 ± 7.57 years, 159.07 ± 6.68 cm, 64.56 ± 12.4 kg, and 25.34 ± 4.38 kg/m², respectively.

Ibandronate treatment significantly improved lumbar spine BMD. The overall effect size (percent change from baseline) was 1.9 ± 1.06 (1–5) years. Prior to entering the trial, 45.7% of the patients had a history of fractures. Average time since menopause in women with postmenopausal osteoporosis (PMO) was 15.39 ± 7.04 years. At the time of entry into the trial, these participants had serum markers measured as vitamin D (30.21 ± 11.6 ng/mL), PTH (49.9 ± 25.24 pg/mL), osteocalcin (23.65 ± 9.88 ng/mL), serum CTX (0.42 ± 0.29 ng/mL), serum PINP (49.73 ± 31.16 ng/mL), BSAP (58.75 ± 19.71 U/L), serum calcium (9.45 ± 0.519 mg/dL), and serum phosphate (3.66 ± 0.588 mg/dL).

Ibandronate treatment significantly improved lumbar spine BMD. The overall effect size (percent change from baseline) was 1.9 ± 1.06 (1–5) years. Prior to entering the trial, 45.7% of the patients had a history of fractures. Average time since menopause in women with postmenopausal osteoporosis (PMO) was 15.39 ± 7.04 years. At the time of entry into the trial, these participants had serum markers measured as vitamin D (30.21 ± 11.6 ng/mL), PTH (49.9 ± 25.24 pg/mL), osteocalcin (23.65 ± 9.88 ng/mL), serum CTX (0.42 ± 0.29 ng/mL), serum PINP (49.73 ± 31.16 ng/mL), BSAP (58.75 ± 19.71 U/L), serum calcium (9.45 ± 0.519 mg/dL), and serum phosphate (3.66 ± 0.588 mg/dL).
was 4.80%, $P < 0.0001$, 95% CI [4.14, 5.45]. Oral intake of ibandronate led to a change of 4.57%, $P < 0.0001$, 95% CI [3.71, 5.42], whereas the effect size of IV infusion was 5.22%, $P < 0.0001$, 95% CI [4.37, 6.07] (Figure 2). There was no significant difference between the efficacy of oral and IV ibandronate administration ($z = 0.264; P = 0.791$).

A subgroup analysis to examine the difference of ibandronate efficacy in improving lumbar spine BMD in postmenopausal women versus all other osteoporotic conditions revealed no significant difference (4.75% vs 4.93%, 95% CIs [4.24, 5.26] and [3.55, 6.31]) between subgroups ($z = 0.067; P = 0.95$; Figure 3). Similarly, there was no significant difference in the percent change from baseline in the lumbar spine BMD between males (5.96% [2.92, 8.99]) and females (4.547% [3.88, 5.21, 4.75]) between subgroups ($z = 0.90; P = 0.367$; Figure S2, http://links.lww.com/MD/A306).

The effect sizes (percent changes in the BMD of lumbar spine) of different doses of orally administered and intravenously infused ibandronate are presented in Table 1 and Figure 4. Only 2 oral dose regimens led to nonsignificant increase in lumbar spine BMD (1 mg/d: 4.65%, $P = 0.285$, 95% CI [-3.87, 13.18] and 0.5 mg/d: 3.60%, $P = 0.38$, 95% CI [-4.43, 11.64]). In the between-dose subgroup analyses, the efficacy of IV 2 mg/3 mo differed significantly from IV 0.5 mg/3 mo ($z = 2.5; P = 0.0124$) and the efficacy of oral 150 mg/mo differed significantly from oral 0.5 mg/mo ($z = 0.479; P = 0.632$). None of the other dose regimens differed significantly in affecting lumbar spine BMD. Besides this, one study each also could not find any significant change in BMD from IV 0.5 mg/mo,32 oral 5 and 10 mg/wk doses.50

Ibandronate treatment also improved total hip BMD significantly. The overall effect size (percent change from baseline) was 2.30%, $P < 0.0001$, 95% CI [1.96, 2.64]. Oral intake of

**FIGURE 3.** Forest chart showing the effect sizes (percent change in the bone mineral density following ibandronate treatment) of postmenopausal women versus all other osteoporotic conditions.
TABLE 1. Overall, by Mode of Administration and Dose Regimen Meta-Analyses, Outcomes (Percent Changes From Baseline in the BMD After Ibandronate Treatment)

| Subgroup                | Effect Size | Dataset | Z*  | P  | I²1, % | I²  |
|-------------------------|-------------|---------|-----|----|--------|-----|
| Lumbar spine BMD by mode|              |         |     |    |        |     |
| Overall                 | 4.80 (4.14, 5.45) | 32      | 14.39 | <0.0001 | 98.4 | 5.01 |
| Oral                    | 4.57 (3.71, 5.42) | 21      | 10.49 | <0.0001 | 98.7 | 5.63 |
| IV                      | 5.22 (4.37, 6.07) | 11      | 12.07 | <0.0001 | 95.1 | 2.69 |
| Lumbar spine BMD by dose|              |         |     |    |        |     |
| IV 1 mg/3 mo            | 4.33 (2.92, 5.74) | 4       | 6   | <0.0001 | 90.5 | 1.55 |
| IV 2 mg/3 mo            | 7.86 (4.74, 10.97) | 5     | 4.95 | <0.0001 | 96.5 | 11.96 |
| IV 3 mg/3 mo            | 4.20 (2.02, 6.37) | 5     | 3.78 | <0.0001 | 96.1 | 5.54 |
| IV 0.5 mg/3 mo          | 3.87 (3.55, 4.20) | 2     | 23.29 | <0.0001 | 0   | 0   |
| 150 mg/mo               | 5.59 (4.28, 6.89) | 13    | 8.39 | <0.0001 | 97.1 | 4.87 |
| 20 mg/wk                | 3.13 (2.60, 3.6) | 2      | 11.53 | <0.0001 | 25   | 0.03 |
| 20 mg intermittent      | 5.69 (5.36, 6.03) | 2    | 33.49 | <0.0001 | 0   | 0   |
| 2.5 mg/d                | 4.38 (2.65, 6.10) | 8    | 4.97 | <0.0001 | 99.2 | 6.07 |
| 1 mg/d                  | 4.65 (3.87, 13.18) | 2    | 1.07 | 0.285 | 99.5 | 37.67 |
| 0.5 mg/d                | 3.60 (–4.43, 11.64) | 2  | 0.88 | 0.38  | 99.5 | 33.43 |
| Total hip BMD by mode   |              |         |     |    |        |     |
| Overall                 | 2.30 (1.96, 2.64) | 27    | 13.42 | <0.0001 | 93.7 | 0.78 |
| Oral                    | 2.13 (1.70, 2.55) | 17    | 9.74 | <0.0001 | 94.8 | 0.84 |
| IV                      | 2.63 (2.07, 3.20) | 10    | 9.09 | <0.0001 | 90.4 | 0.74 |
| Total hip BMD by dose   |              |         |     |    |        |     |
| IV 1 mg/3 mo            | 2.24 (1.91, 2.58) | 3     | 13.1 | <0.0001 | 0   | 0   |
| IV 2 mg/3 mo            | 2.90 (2.55, 3.25) | 2     | 16.34 | <0.0001 | 0   | 0   |
| IV 3 mg/3 mo            | 3.51 (2.32, 4.70) | 3     | 5.8  | <0.0001 | 75.6 | 0.79 |
| IV 0.5 mg/3 mo          | 1.37 (0.54, 2.21) | 2    | 3.22 | <0.0001 | 49.4 | 0.22 |
| 150 mg/mo               | 1.73 (0.89, 2.57) | 8    | 4.03 | <0.0001 | 95.6 | 1.09 |
| 20 mg/wk                | 2.05 (1.67, 2.43) | 2    | 10.58 | <0.0001 | 0   | 0   |
| 20 mg intermittent      | 3.03 (2.79, 3.27) | 2    | 25.11 | <0.0001 | 0   | 0   |
| 2.5 mg/d                | 2.70 (1.97, 3.42) | 5    | 7.27 | <0.0001 | 91.7 | 0.61 |

BMD = bone mineral density, IV = intravenous.

1Significance test(s) of ES = 0.

2I²: the variation in effective size attributable to heterogeneity.

Ibandronate led to a change of 2.13%, P < 0.0001, 95% CI [1.70, 2.55], whereas the effect size of IV infusion mode was 2.63%, P < 0.0001, 95% CI [2.07, 3.20] (Figure S3, http://links.lww.com/MD/A306). There was no significant difference between the efficacy of these 2 routes of ibandronate administration (z = 1.389; P = 0.1645). The effect sizes of different doses of orally administered and intravenously infused ibandronate are presented in Table 1 and Figure S4, http://links.lww.com/MD/A306. None of the dose regimens differed significantly in affecting total hip BMD.

Both the modes of ibandronate administration significantly decreased serum markers of bone resorption (Table 2). Percent changes from baseline in these markers were –46.53%, P < 0.0001, 95% CI [–53.16, –39.91] for CTX, –24.03%, P < 0.0001, 95% CI [–31.28, –16.77] for BSAP, and –50.17%, P < 0.0001, 95% CI [–64.13, –36.20] for PINP. There were no significant differences in the changes in these serum markers with regard to the mode of administration. Parathyroid hormone levels remained unaffected from ibandronate treatment (3.03%, P = 0.439, 95% CI [–5.06, 11.66]).

DISCUSSION

This study was designed to seek updated evidence regarding the dose-wise efficacy of ibandronate in the treatment or prevention of osteoporosis. The majority of dose regimens were found to be significantly efficacious and there was no significant difference between the efficacies of IV ibandronate infusions of 1 to 3 mg every third month or orally administered doses including 150 mg/mo, 20 mg/wk, or 1 to 2.5 mg daily. Only 0.5 and 1 mg/d oral dose regimens led to nonsignificant increases in lumbar spine BMD.

Within the ibandronate treatment period (about 2 years, on average), the annual incidence of fractures was 2.34 ± 1.58% in the study population in which 45.73 ± 23.41% patients had a history of fractures. Data from placebo-controlled studies included in this meta-analysis revealed that annual incidence of fractures during the treatment period was 3.52 ± 2.31% in placebo versus 2.1 ± 1.02% in ibandronate groups when the percent increase in the BMD was 4.22% in lumbar spine and 2.15% in total hip in the ibandronate-treated participants of these placebo-controlled trials. Thus, ibandronate treatment was associated with a 1.42 ± 0.52% reduction in the relative increase of fractures. These results further support the notion that BMD is a strong predictor of fracture risk and is, therefore, an appropriate surrogate marker of bone strength.55

So far, it is known that ibandronate therapy reduces vertebral fracture as well as hip fracture risk reduction. In general, in comparison with oral 2.5 mg/d dose, oral 150 mg/
mo or IV ibandronate treatments are associated with a longer time to fracture event and lower fracture rates.56

In this study, we have noted a slightly higher ibandronate efficacy in males than females, but this finding was not statistically significant. In females, estrogen status is an important determinant of bone health as has been demonstrated in an ovariectomized primate model.57 A relatively higher risk of osteoporotic fractures in women is also attributed to the anatomical differences. Although trabecular thinning with increasing age is seen in both the sexes, trabecular dropout is observed only in women. Men have larger bones with a lesser degree of cortical thinning with age.58 However, although the risk is lower, osteoporotic fractures constitute an important cause of morbidity and mortality also in men.59

Timely treatment initiation and adherence to ibandronate therapy can increase efficacious outcomes. Intravenous administration of ibandronate prevents gastrointestinal intolerance and ensures better compliance leading to improved efficacy. However, tolerability characteristics such as the acute phase (flu-like) cytokine response and safety properties such as the risk of over-suppressed bone turnover, renal toxicity, and jaw osteonecrosis impose concerns over IV use.60,61 On the contrary, the complex

FIGURE 4. Forest chart showing dose-wise effect sizes (percent change in the bone mineral density following ibandronate treatment) achieved in this meta-analysis.
dosing modalities of oral route administration including fasting, regularity, and adverse effects can compromise compliance and adherence to regular intake.\textsuperscript{62}

With its multiopinion dosing, convenient IV infusion, and better safety profile, ibandronate appears to have advantageous over its contemporaneous oral or IV bisphosphonates. In a pooled analysis of clinical trials with over 6000 subjects, ibandronate treatment was not found to increase the risk of atrial fibrillation.\textsuperscript{63} The bioavailability of ibandronate also varies in different geographic populations. Although the bioavailability of oral ibandronate is 0.91\% in a Japanese population, it is 0.63\% in western populations. Thus, an optimal oral dose of 100 mg/mo is suggested in Japan, but 150 mg/mo in the west.\textsuperscript{64} This factor might also have some impact on the outcomes of this meta-analysis.

**CONCLUSION**

Both routes of ibandronate administration significantly increase BMD and thus potentially reduce the risk of osteoporotic fractures. Overall change in BMD following ibandronate treatment did not differ significantly by oral versus IV administration or by PMO versus other forms of osteoporosis or sex. Only low doses of oral administration (0.5 and 1 mg/d) produce a non-significant increase in BMD. Serum markers of bone resorption including BSAP,CTX, and PINP are significantly reduced in the ibandronate-treated patients. Parathyroid hormone levels remained unaffected by the ibandronate treatment.

**REFERENCES**

1. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res.* 2007;22:465-475.

2. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. *Osteoporos Int.* 1997;7:407-413.

3. Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. *Bone.* 1994;15:551-555.

4. Orwell ES, Klein RF. Osteoporosis in men. *Endocr Rev.* 1995;16:87-116.

5. Demontiero O, Duque G. Once-yearly zoledronic acid in hip fracture prevention. *Clin Interv Aging.* 2009;4:153-164.

6. Guggenbuhl P. Osteoporosis in males and females: is there really a difference? *Joint Bone Spine.* 2009;76:595-601.

7. Goncalves MJ, Rodrigues AM, Canhao H, et al. Osteoporosis: from bone biology to individual treatment decision. *Acta Med Port.* 2013;26:445-455.

8. McClung M, Harris ST, Paul D, et al. Bisphosphonate therapy for osteoporosis or osteopenia derived from in vivo markers in patients with haemophilia A and B and increased risk for fracture. *Thromb Haemost.* 2013;110:257-263.

9. Bock O, Börst H, Beller G, et al. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal women with osteoporosis. *Bone.* 2011;49:13-20.

10. Rakel A, Boucher A, Ste-Marie LG. Role of zoledronic acid in the prevention and treatment of osteoporosis. *Clin Interv Aging.* 2011;6:89-99.

11. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. *Bone.* 2004;34:881-889.

12. Anagnostis P, Vyzantiadis TA, Charizopoulou M, et al. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture. *Thromb Haemost.* 2013;110:257-263.

13. Bock O, Börst H, Beller G, et al. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. *Bone.* 2012;50:317-324.

14. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. *Bone.* 2005;37:651-654.

15. Becker RR, Weinstein RS, Chesnut CH 3rd et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in
women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004;15:231–237.

16. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88:4609–4615.

17. Bianchi G, Czerwinski E, Kenwright A, et al. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 2-5-year data from the DIVA study. Osteoporos Int. 2012;23:1769–1778.

18. Delmas PD, Adami S, Strugala C, et al. Infusion of ibandronate once every 28 days in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838–1846.

19. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35:488–497.

20. Recker RR, Ste-Marie LG, Langdahl B, et al. Efficacy of intermittent intravenous ibandronate injections in bone quality and microarchitecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010;46:660–665.

21. Miller PD, Recker RR, Harris S, et al. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int. 2014;25:349–357.

22. Pasalic KS. ESTHER Study Group. Efficacy and safety of once-monthly ibandronate treatment in patients with low bone mineral density-ESTHER Study: 24 months of follow-up. Srp Arh Celok Lek. 2012;140:722–727.

23. Gonnelli S, Caffarelli C, Tanzilli L, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014;61:27–32.

24. Guanabens N, Monegal A, Cerda D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58:2070–2078.

25. Hakala M, Kroger H, Vallela H, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012;41:260–266.

26. Kaukerber D, Schmidt B, Lehmann G, et al. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplant Proc. 2012;44:1362–1367.

27. Klaus J, Reinhagen M, Herdt K, et al. Intravenous ibandronate or sodium-fluoride: a 3.5 years study on bone density and fractures in Crohn’s disease patients with osteoporosis. J Gastrointestin Liver Dis. 2011;20:141–148.

28. Li EK, Zhu TY, Hung VY, et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther. 2010;12:R198.

29. Li M, Xing XP, Zhang ZL, et al. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. J Bone Miner Res. 2010;28:299–305.

30. McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004;19:11–18.

31. McClung MR, Bolognese MA, Sedarati F, et al. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone. 2009;44:418–422.

32. Mitsopoulos E, Ginkopoulou E, Economidou D, et al. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study. Am J Nephrol. 2012;36:238–244.

33. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315–1322.

34. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654–661.

35. Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol. 2008;27:955–960.

36. Emkey R, Delmas PD, Bolognese M, et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther. 2009;31:751–761.

37. Miller PD, Epstein S, Sedarati F, et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2008;24:207–213.

38. Hagono H, Yoshida S, Hashimoto J, et al. Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcif Tissue Int. 2014;95:557–563.

39. Nakamura T, Nakano T, Ito M, et al. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013;93:137–146.

40. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996;19:527–533.

41. Recker R, Stakkestad JA, Chesnut CH 3rd et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004;34:890–899.

42. Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121:1291–1299.

43. Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res. 2001;16:1871–1878.

44. Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14:801–807.

45. Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatol (Oxford). 2003;42:743–749.

46. Senn C, Günther B, Popp AW, et al. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int. 2014;25:1945–1951.

47. Smerud KT, Dolgos S, Olsen IC, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on
bone loss following renal transplantation. *Am J Transplant.*
2012;12:3316–3325.

48. Genant HK, Lewiecki EM, Fuerst T, et al. Effect of monthly ibandronate on hip structural geometry in men with low bone density. *Osteoporos Int.* 2012;23:257–265.

49. Orwell ES, Binkley NC, Lewiecki EM, et al. Efficacy and safety of monthly ibandronate in men with low bone density. *Bone.*
2010;46:970–976.

50. Tanko LB, Felsenberg D, Czerwinski E, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. *J Intern Med.*
2003;254:159–167.

51. Tanko LB, McClung MR, Schimmer RC, et al. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. *Bone.*
2003;32:421–426.

52. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. *Am J Med.*
1997;103:298–307.

53. Misof BM, Patsch JM, Roschger P, et al. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. *J Bone Miner Res.*
2014;29:440–449.

54. Paggiosi MA, Peel N, McCloskey E, et al. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. *Osteoporos Int.*
2014;25:2729–2741.

55. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. *J Bone Miner Res.*
2003;20:1185–1194.

56. Inderjeeth CA, Glendening P, Ratnagobal S, et al. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. *Int J Womens Health.*
2014;7:7–17.

57. Muller R, Hannan M, Smith SY, et al. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. *J Bone Miner Res.*
2004;19:1787–1796.

58. Chen H, Zhou X, Fujita H, et al. Age-related changes in trabecular and cortical bone microstructure. *Int J Endocrinol.*
2013;2013:1–9.

59. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. *J Am Geriatr Soc.*
2002;50:1644–1650.

60. Miller PD. Anti-resorptives in the management of osteoporosis. *Best Pract Res Clin Endocrinol Metab.*
2008;22:849–868.

61. Mottaghi P. Intravenous bisphosphonates for postmenopausal osteoporosis. *J Rs Med Sci.*
2010;15:175–184.

62. Vytisalova M, Touskova T, Ladova K, et al. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. *Climacteric.*
2015;24:1–9.

63. Lewiecki EM, Cooper C, Thompson E, et al. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. *Int J Clin Pract.*
2010;64:821–826.

64. Nakai K, Tobinai M, Hashimoto J, et al. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. *Eur J Drug Metab Pharmacokinet.*
2014;do: 10.1007/s13318-014-0242-5.